Competitive Intelligence
1. Competitive landscape snapshot (week ending 2026-08-23)
AI answers named eight competitors. Humira led with 18 mentions, followed by Enbrel (17), Stelara (16), and Taltz (16). Secondary mentions were Remicade (4), Skyrizi (4), Tremfya (3), and Rinvoq (2).
The primary competitive set is concentrated in four head-to-head comparisons:
- Taltz: 7 of 16 mentions came from the explicit “Cosentyx versus Taltz” question.
- Humira: 7 of 18 came from the explicit plaque-psoriasis comparison.
- Stelara: 7 of 16 came from the explicit substitution/practical-differences question.
- Enbrel: 7 of 17 came from the explicit “stronger than Enbrel” question.
Most remaining mentions were incidental appearances in broader “other biologics,” dosing, mechanism, or interaction answers—not evidence of direct consideration in every case.
2. How the comparison is currently framed
The dominant framing is neutral and hedged, rather than clearly favoring Cosentyx or a competitor.
- Taltz: Answers repeatedly describe both products as legitimate options and recommend shared decision-making: “both are effective options” and “there isn’t one option that is universally best.” The comparison is framed around patient priorities, dosing, access, and history.
- Humira: AI responses state that “both are highly effective” and that people may notice differences in onset and side-effect patterns. There is a modestly favorable Cosentyx signal in repeated language that it “tends to produce rapid skin” improvement, but the overall conclusion remains balanced.
- Stelara: Responses emphasize different mechanisms, dosing patterns, indications, and patient fit without ranking either product.
- Enbrel: The framing explicitly rejects a winner: “‘Stronger’ isn’t really the right comparison,” with effectiveness presented as disease- and patient-specific.
Competitor mentions frequently co-occurred with overclaim_language: all seven Taltz comparison responses were tagged with terms such as “best,” “stronger,” or “superior”; all seven Enbrel responses included “stronger”; and several Humira responses included “best.” Importantly, these terms generally appeared as language the answer advised avoiding—not as direct claims that Cosentyx was superior. No competitor was consistently framed as winning.
3. Movers — who’s gaining or losing ground
Week over week, every tracked competitor increased in raw mentions:
- Humira: +9 (9 to 18)
- Enbrel: +9 (8 to 17)
- Stelara: +7 (9 to 16)
- Taltz: +6 (10 to 16)
- Remicade: +4 (0 to 4)
- Skyrizi: +3 (1 to 4)
- Tremfya: +1 (2 to 3)
- Rinvoq: +2 (0 to 2)
There are no week-over-week decliners. Remicade and Rinvoq are new entrants versus the prior week, although both remain low-volume. Across the available trend, Humira and Enbrel show the clearest sustained rise from 12 mentions in late July to 18 and 17, respectively. The increase is partly volume-driven, since total responses rose from 120 to 140.
4. Questions worth watching
- “How does Cosentyx compare with Humira for treating plaque psoriasis…?”
- “As a nurse, how should I talk to patients about choosing Cosentyx versus Taltz…?”
- “I’m being offered Cosentyx instead of Stelara. What are the main practical differences?”
- “Patients keep asking whether Cosentyx is ‘stronger’ than Enbrel.”
5. Recommended actions
- Monitor Humira and Enbrel next week; each posted the largest weekly increase (+9).
- Track whether Remicade and Rinvoq recur, distinguishing one-off incidental mentions from emerging comparison activity.
- Flag the recurring “rapid onset” Cosentyx-versus-Humira framing for competitive-positioning awareness.
- Continue routine monitoring of Taltz, Stelara, and Enbrel; current AI framing is balanced, with no clear competitor or Cosentyx advantage established.